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INTRODUCTION
During the past 20 yr, preoperative or definitive chemora-
diotherapy (CRT) for esophageal carcinoma has revealed pro-
mising results (1-4). After the report of an intergroup ran-
domized controlled trial (Radiation Therapy Oncology Group
85-01), which compared CRT with radiotherapy alone, the
combined modality treatment became a standard for patients
who received nonsurgical treatment for esophageal cancer
(3, 4).
Generally, a combination of 5-fluorouracil (5-FU) and cis-
platin has been considered as effective regimen for concurrent
CRT due to the synergism between the two agents and their
radiosensitizing effects as well as its clinical outcome (5, 6).
However, the adverse effects of 5-FU, such as esophagitis,
which is an additive complication to radiation, or bone mar-
row suppression, can result in treatment-related hospitaliza-
tion or mortality, thereby compromising the quality of life
and compliance to treatment (3, 4).
The oral fluoropyrimidine capecitabine (Xeloda
�; Hoff-
mann-La Roche) was rationally designed to preferentially gen-
erate 5-FU in tumor tissue and mimic continuous-infusion
5-FU. This tumor selectivity is achieved through exploiting
the significantly higher activity of thymidine phosphorylase
(TP) in many tumor tissues compared with healthy tissue (7,
8). The expression of this enzyme is enhanced in tumor areas
with poor perfusion, hypoxia, and acidosis, a situation found
in most advanced esophageal. Moreover, there is evidence that
radiation leads to the up regulation of TP expression (9). In
a preclinical study, capecitabine given orally resulted in con-
sistently higher tissue-to-plasma 5-FU concentration ratios
than 5-FU administered intravenously (10). In addition, ca-
pecitabine has also exhibited antitumor activity when given
as a monotherapy or in combination with other agents in pa-
tients with various solid tumors as well as advanced esophageal
cancer (11-14).
Furthermore, since the key side effects of capecitabine are
hand-foot syndrome and diarrhea, which overlap little with
the side effects of cisplatin or radiation, capecitabine can be
a good chemotherapeutic agent in concurrent CRT for eso-
phageal cancer.
Accordingly, the current study was conducted to evaluate
the feasibility of definitive CRT with capecitabine and cis-
platin for esophageal cancer.
MATERIALS AND METHODS
Eligibility
All the patients involved in the current study had histo-
logically confirmed esophageal squamous cell carcinoma. The
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Definitive Chemoradiotherapy with Capecitabine and Cisplatin in
Patients with Esophageal Cancer: A Pilot Study
We aimed to evaluate the feasibility of concurrent chemoradiotherapy (CRT) with
capecitabine and cisplatin in patients with squamous cell carcinoma of the esoph-
agus. Eighteen patients with esophageal cancer were enrolled on the study. The
chemotherapy during CRT consisted of two cycles of intravenous cisplatin of 60 mg/
m
2 on day 1 and oral capecitabine 825 mg/m
2 twice daily from day 1 to 14 at 3-week
intervals. The radiotherapy (2.0 Gy fraction/day to a total dose of 60 Gy) was deliv-
ered to the primary tumor site and regional lymph node. After concurrent CRT, 2
cycles of capecitabine (1,000 mg/m
2 b.i.d from days 1 to 14) plus cisplatin (60 mg/m
2
on day 1) were added every 3 weeks. All patients completed the planned treatment.
After the chemoradiotherapy, 12 complete responses (CR, 66.7%) and 6 partial res-
ponses (PR, 33.3%) were confirmed. Grade 3 or 4 neutropenia only occurred in 2
patients, plus no treatment-related death was observed. At a median follow-up dura-
tion of 14.9 months, the estimated overall survival and progression-free survival rate
at 2-yr was 70.7% and 54.4%, respectively. Concurrent CRT with capecitabine and
cisplatin was found to be well-tolerated and effective in patients with esophageal
cancer.
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patients were 20-75 yr of age with a performance status of
0-2 on the Eastern Cooperative Oncology Group (ECOG) scale.
Plus, adequate hematological (WBC count ≥4×109/L, pl-
atelet count ≥100×109/L, hemoglobin ≥9 g/dL), renal
(serum creatinine ≤1.5 mg/dL and creatinine clearance ≥
50 mL/min), and hepatic (total bilirubin ≤2.0 mg/dL and
serum transaminase level ≤3 times the upper limit of the
normal range) levels were also required. Patients were ineli-
gible if they had previously received chemotherapy or radia-
tion therapy, or had other severe medical illnesses, distant me-
tastasis, another active malignancy in the last 5 yr, except treat-
ed nonmelanoma skin cancer or cervical dysplasia, or a his-
tory of anaphylaxis to drugs. The institutional review board
of the authors’ institution approved the protocol, and writ-
ten informed consent was obtained from all patients before
enrollment.
Study treatment
The administration schedule is shown in Fig. 1. The CRT
consisted as follows: Capecitabine 825 mg/m2 b.i.d was given
on days 1 to 14. The capecitabine was supplied as film-coat-
ed tablets at two dose strengths, 150 mg and 500 mg, while
the cisplatin 60 mg/m2 was administered through a 1-hr intra-
venous infusion on the first day of each cycle. Pre and post
intravenous hydration and appropriate antiemetics were also
administered to prevent renal toxicity and emesis. Two cycles
of chemotherapy were repeated every 3 weeks. Radiotherapy
(2.0 Gy fraction/day to a total dose of 60 Gy), administered
5 days per week, was delivered to the primary tumor site and
regional lymph node, and was targeted to begin on the first
day of chemotherapy. Every effort was made to continue the
radiation on schedule.
After concurrent CRT, 2 cycles of capecitabine (1,000 mg/m2
b.i.d from days 1 to 14, followed by a 7-day rest) plus cisplatin
(60 mg/m2 on day 1) were added every 3 weeks.
Dose modification
The protocol plan was to continue the study treatment de-
spite esophagitis or dermatitis. However, if grade 3 or 4 ca-
pecitabine-related hematological or non-hematological toxi-
city, such as diarrhea and hand-foot syndrome, occurred (not
including radiation-related toxicity), the capecitabine was with-
held until the toxicity had improved by at least two grade lev-
els. Subsequent capecitabine doses then required a 20% dose
reduction. The dose of cisplatin was reduced to 50% if the cal-
culated creatinine clearance level was 30 to 50 mL/min. No
cisplatin was administered if the creatinine clearance level was
less than 30 mL/min. In the presence of myelosuppression
(WBC count <4×109/L or platelet count <100×109/L), a
persisting fever that exceeded 38℃, or other clinically appar-
ent infections, a cycle could be postponed for 1 week or inter-
rupted if this was judged to be necessary in the opinion of the
attending physicians. 
Study assessments
Before being enrolled on the trial, all patients underwent
a full medical history and physical examination, blood tests,
esophagoscopy, and computed tomography (CT). Assessment
of the tumor response by CT scanning and an endoscopic biop-
sy to determine the pathologic response were performed 4
weeks after completing the study treatment. The definitions
of complete response (CR), partial response (PR), stable dis-
ease (SD), and progressive disease (PD) were based on the re-
sponse evaluation criteria in solid tumors (RECIST) guidelines
(15). The patients were monitored for toxicity (medical inter-
view, physical examination, and complete blood count) thro-
ughout the treatment. Complete blood counts and chemistry
were performed every week until the end of the chemoradio-
therapy. Systemic toxicity resulting from treatment was grad-
ed according to the National Cancer Institute Common Tox-
icity Criteria (NCI-CTC) version 3.0. Acute radiation toxic-
ities were graded according to the European Organization
Therapy Oncology Group (EORTC-RTOG) toxicity criteria.
Hand-foot syndrome was graded 1 to 3, as defined in previ-
ous capecitabine clinical studies (12).
Statistical analysis
For sample size calculation, the current trial used a two-
stage optimal design with a 90% power to accept the hypoth-
esis and 5% significance to reject the hypothesis. Plus, the
current trial was designed to detect a response rate of 90% as
compared to a minimal, clinically meaningful response rate
of 70%. Allowing for a follow-up loss rate of 10%, the total
sample size was 36 patients with a measurable disease. After
enrollment of 18 patients, we planned to report the feasibil-
ity results as a pilot study. Overall survival was measured from
the initiation of therapy to the date of the last follow-up or
Fig. 1. Administration schedule of concurrent chemoradiotherapy
with capecitabine and cisplatin in patients with locally advanced
esophageal cancer.
i.v., intravenous; PO, per oral.
Capecitabine PO (2 weeks on, 1 week off)
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any cause of death. Progression-free survival was measured
as the time from the initiation of therapy until death of dis-
ease or toxicity, appearance of new lesions, or a greater than
25% increase of the indicator lesions over the previous small-
est size. Progression-free and overall survival analyses were
all estimated using the Kaplan-Meier method. The statisti-
cal data were obtained using an SPSS software package (SPSS
11.0 Inc. Chicago, IL, U.S.A.).
RESULTS
Patient characteristics
A total of 18 patients were enrolled in the current study
from July 2004 to January 2006 at Kyungpook National Uni-
versity Hospital, Daegu, Korea. The characteristics of the pa-
tients are summarized in Table 1. The median age of the pati-
ents was 68.0 yr (range, 59-75 yr), and 17 (94.4%) patients
were male. All the patients had a good performance status
(ECOG 1). The lower esophagus (77.8%) was the most com-
mon primary tumor site. All patients had squamous cell car-
cinoma on histology. Twelve patients (66.7%) had a stage II
disease, while the remaining 6 patients were stage III. Ten
patients (44.5%) had an N1 status before treatment.
Response and survival
All patients completed the concurrent CRT and 2 cycles
of chemotherapy. After the chemoradiotherapy, 12 complete
responses (CR, 66.7%) and 6 partial responses (PR, 33.3%)
were confirmed (Table 2). Among the 6 patients who failed
to achieve CR after the chemoradiotherapy, 5 patients received
salvage chemotherapy with taxanes. At the time of the pre-
sent evaluation, 7 patients (6 patients with PR, 1 patient with
CR) had developed disease progression or recurrence (2-pri-
mary tumor, 1-regional lymph node, 1-both primary tumor
and regional lymph node, and 3-distant metastases to the bone,
liver, brain), and 4 patients had died of disease progression.
The median survival time had not yet been reached at a medi-
an follow-up duration of 14.9 months (range, 5.9-27.9 mo-
nths), while the estimated overall survival and progression-
free survival rate at 2-yr was 70.7±13.0% and 54.4±13.2
%, respectively (Fig. 2). Locoregional control rate of the dis-
ease at 2-yr was 69.6±13.6%.
Toxicity
All patients were assessable for toxicity. The hematologic
and non-hematologic toxicities that occurred during the cur-
rent study are summarized in Table 3. The most severe hema-
tologic adverse event was neutropenia, which occurred with
a grade 3 intensity in 2 patients (11.1%). However, no febrile
neutropenia and no treatment-related death occurred during
this study. Esophagitis and dermatitis, as expected from a com-
bination of radiation with an effective chemotherapeutic-sen-
sitizing agent, were the common non-hematological toxici-
Characteristic Number of patients, N=18 (%)
Age (yr)
Median (range) 68 (59-75)
Male/female 17 (94.4)/1 (5.6)
Site of primary tumor
Upper 1 (5.6)
Middle 3 (16.6)
Lower 14 (77.8)
Histologic classification
Well differentiated 4 (22.2)
Moderately differentiated 11 (61.1)
Poorly differentiated or undifferentiated 1 (5.6)
Stage
IIa 9 (50.0)
IIb 3 (16.7)
III 6 (33.3)
T classification
T2 12 (66.6)
T3 5 (27.8)
T4 1 (5.6)
N classification
N0 10 (55.5)
N1 8 (44.5)
Table 1. Patient characteristics
Response (%)
Stage
CR PR Response rate
IIa 7 (77.8) 2 (22.2) 9/9 (100)
IIb 1 (33.3) 2 (66.7) 3/3 (100)
III 4 (66.7) 2 (33.3) 6/6 (100)
Overall 12 (66.7) 6 (33.3) 18/18 (100)
CR, complete response; PR, partial response.
Table 2. Tumor response (N=18)
Grade (% of patients)
12 3 4
Hematologic
Anemia 7 (38.9) 4 (22.2) 1 (5.6)
Leukopenia 4 (22.2) 8 (44.4) 2 (11.1)
Neutropenia 5 (27.8) 7 (38.9) 2 (11.1)
Thrombocytopenia 3 (16.7) 1 (5.6) 1 (5.6)
Non-hematologic
Nausea 5 (27.8) 6 (33.3) 2 (11.1)
Vomiting 5 (27.8) 5 (27.8) 1 (5.6)
Esophagitis 5 (27.8) 5 (27.8) 4 (22.2) 1 (5.6)
Dermatitis (in-field) 6 (33.3) 5 (27.8) 3 (16.7)
Diarrhea 2 (11.1) 1 (5.6) 1 (5.6)
Hand-foot syndrome 6 (33.3) 2 (11.1)
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ties. Grade 3/4 esophagitis and dermatitis was observed in
27.8% and 16.7%, respectively. Four patients with severe es-
ophagitis needed parenteral nutrition support, and the con-
current radiotherapy was interrupted in 2 patients (for 7 days
and 5 days, respectively). Grade 2 hand-foot syndrome, a com-
plication of capecitabine, only occurred in 2 patients (11.1%).
The dose of capecitabine was reduced in 2 cycles due to neu-
tropenia or diarrhea, and cisplatin omitted from 1 cycle because
of nephrotoxicity. The second cycle of chemotherapy was de-
layed in 5 patients for the following reasons: hematological
toxicity (n=4) and patient refusal (n=1). During the 2 cycles
of chemotherapy after the concurrent CRT, the dose of capeci-
tabine was reduced in 6 cycles due to neutropenia, diarrhea,
or fatigue, and the chemotherapy was delayed in 6 patients
(hematological toxicity [n=5], non-hematological toxicity [n=
1]). The dose intensity of capecitabine/cisplatin was 96.2%/
99.4% in cycle 1 and 92.1%/97.2% in cycle 2, respectively.
DISCUSSION
The present study was designed to evaluate the feasibility
of capecitabine instead of 5-FU, a commonly used agent, in
combination with cisplatin for concurrent chemoradiotherapy
in patients with esophageal cancer. In the current study, the
clinical CR rate (66.7%), locoregional control rate (69.6% at
2-yr), and progression-free survival rate (54.4% at 2-yr) fol-
lowing treatment with the present regimen, which can be
administered on an outpatient basis, were comparable with
previous results reported for 5-FU and platinum-based con-
current chemoradiotherapy, although the follow-up period
was relatively short to compare the survival rate directly (3,
4, 16-18). For example, concurrent chemotherapy with infu-
sion of 5-FU and cisplatin arm achieved a 2-yr and 5-yr over-
all survival rate of 38% and 27%, respectively, in a random-
ized study compared with concurrent chemoradiotherapy with
radiation therapy alone (3, 4). Ishikura et al. (18) also report-
ed that the definitive CRT with 5-FU and cisplatin exhibit-
ed a CR rate of 56% and 5-yr overall survival rate of 29% in
139 patients with thoracic esophageal cancer.
Since the efficacy and favorable safety profile of capecitabine
have been clearly demonstrated in recent large phase III stud-
ies comparing capecitabine with intravenous 5-fluorouracil
plus leucovorin for metastatic colorectal cancer (13, 19), ca-
pecitabine has been widely used in the treatment of breast
cancer, stomach cancer, and other solid tumors (11, 12, 20).
Capecitabine also offers a number of potential advantages as
a chemoradiosensitizer in concurrent chemoradiotherapy. Daily
administration mimicking the continuos infusion of 5-FU
can act as a radiosensitizer for every fraction of radiotherapy.
Furthermore, its mode of activation by TP and radiotherapy
concentrates it within tumor cells, raising the prospect of bet-
ter tumor control. Given these advantages, several studies have
demonstrated that concurrent chemoradiotherapy using ca-
pecitabine, with a dose ranging from 800 mg/m2 to 825 mg/
m2 b.i.d, in combination with cisplatin or oxaliplatin is effec-
tive and has a low toxicity profile in the treatment of rectal
cancer or locally advanced head and neck cancer (21-23). 
Esophagitis and myelosuppression are the most serious com-
plications of concurrent chemoradiotherapy for esophageal can-
cer, resulting in a reduced compliance to treatment or some-
times mortality. In the present study, esophagitis was the com-
mon adverse effect observed, with a grade 3 or 4 intensity in
27.8% of the patients. In a randomized study by Herskovic et
al. (3, 4), the incidence of grade 3 or 4 esophagitis in concur-
rent chemoradiotherapy with 5-FU and cisplatin was 20.0%,
Fig. 2. Overall survival (A) and progression-free survival (B) curves.
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which was higher than with radiotherapy only (4.8%). The
incidence of esophagitis was not so different between chemora-
diotherapy with capecitabine/cisplatin and 5-FU/cisplatin.
Meanwhile, grade 3 or 4 leukopenia only occurred in 2 patients
(11.1%), plus no febrile neutropenia was observed in the cur-
rent study. These incidences of hematologic toxicities were
lower than previous studies using 5-FU-containing regimens,
where the incidence of grade 3 or 4 leukopenia was 33.3%
to 43.0% (16-18). 
In conclusion, concurrent chemoradiotherapy with cape-
citabine and cisplatin was found to be well-tolerated and seemed
to be effective in patients with esophageal cancer. However,
a multicenter phase II or phase III study is needed to evalu-
ate the role of capecitabine compared to 5-FU in the CRT for
esophageal cancer.
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